Aimedbio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 50

Employees

  • Stock Symbol
  • 0009K0

Stock Symbol

  • Investments
  • 5

Aimedbio General Information

Description

Operator of a healthcare company intended to serve patients with serious brain diseases. The company provides therapeutic systems and medicines for neuro-oncological and degenerative diseases, enabling patients with refractory brain disease, including cancer, to have an improved quality of life.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 9th Floor, 10th Floor, 11th Floor MK Tower
  • 67 Jeongui-ro, Songpa-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 9th Floor, 10th Floor, 11th Floor MK Tower
  • 67 Jeongui-ro, Songpa-gu
  • Seoul
  • South Korea
+82

Aimedbio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aimedbio Financials Summary

As of 31-Dec-2025, Aimedbio has a trailing 12-month revenue of $29.1M.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024
Revenue 29,077 29,077 8,648
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aimedbio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aimedbio‘s full profile, request access.

Request a free trial

Aimedbio Patents

Aimedbio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026216855-A1 Anti-ror1 antibody-drug conjugate and use thereof Pending 07-Apr-2025
WO-2026151284-A1 Anti-cdcp1 antibody or antigen-binding fragment thereof, antibody-drug conjugate comprising the same, and uses thereof Pending 10-Jan-2025
WO-2026038910-A1 Site-specific antibody-drug conjugates comprising benzoselenophene-based compound and use thereof Pending 16-Aug-2024
WO-2026035116-A1 Linker-drug conjugate and antibody-drug conjugate both comprising silatecan derivative Pending 08-Aug-2024
AU-2024414179-A1 A pharmaceutical composition of anti-fgfr3 antibody drug conjugate and applications thereof Pending 27-Dec-2023 A61P35/00
To view Aimedbio’s complete patent history, request access »

Aimedbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aimedbio Investments (5)

Aimedbio’s most recent deal was a Later Stage VC with Regen Innopharm for . The deal was made on 09-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Regen Innopharm 09-Nov-2026 Later Stage VC Biotechnology
Inocras 03-Aug-2026 Later Stage VC Other Pharmaceuticals and Biotechnology
AIVIS 03-Feb-2026 Later Stage VC Decision/Risk Analysis
Regen Innopharm 01-Mar-2025 Seed Round Biotechnology
SL Therapeutics 04-Mar-2021 PIPE Diagnostic Equipment
To view Aimedbio’s complete investments history, request access »

Aimedbio FAQs

  • When was Aimedbio founded?

    Aimedbio was founded in 2018.

  • Where is Aimedbio headquartered?

    Aimedbio is headquartered in Seoul, South Korea.

  • What is the size of Aimedbio?

    Aimedbio has 50 total employees.

  • What industry is Aimedbio in?

    Aimedbio’s primary industry is Drug Discovery.

  • Is Aimedbio a private or public company?

    Aimedbio is a Public company.

  • What is Aimedbio’s stock symbol?

    The ticker symbol for Aimedbio is 0009K0.

  • What is Aimedbio’s current revenue?

    The trailing twelve month revenue for Aimedbio is $29.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process